These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 19479954)
41. Human immunodeficiency virus type 1-anchored CD40 ligand induces secretion of the chemokine interleukin-8 by human primary macrophages. Maurais E; Cantin R; Tremblay MJ Virology; 2009 Mar; 385(1):227-32. PubMed ID: 19101003 [TBL] [Abstract][Full Text] [Related]
42. Molecular characterization of patients with X-linked Hyper-IgM syndrome: description of two novel CD40L mutations. Rangel-Santos A; Wakim VL; Jacob CM; Pastorino AC; Cunha JM; Collanieri AC; Niemela JE; Grumach AS; Duarte AJ; Moraes-Vasconcelos D; Oliveira JB Scand J Immunol; 2009 Feb; 69(2):169-73. PubMed ID: 19170966 [TBL] [Abstract][Full Text] [Related]
43. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. Ghia P; Chiorazzi N; Stamatopoulos K J Intern Med; 2008 Dec; 264(6):549-62. PubMed ID: 19017179 [TBL] [Abstract][Full Text] [Related]
44. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis. Munroe ME Semin Immunol; 2009 Oct; 21(5):283-8. PubMed ID: 19539498 [TBL] [Abstract][Full Text] [Related]
45. The structural basis of hyper IgM deficiency - CD40L mutations. Thusberg J; Vihinen M Protein Eng Des Sel; 2007 Mar; 20(3):133-41. PubMed ID: 17307885 [TBL] [Abstract][Full Text] [Related]
46. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Rizvi M; Pathak D; Freedman JE; Chakrabarti S Trends Mol Med; 2008 Dec; 14(12):530-8. PubMed ID: 18977174 [TBL] [Abstract][Full Text] [Related]
47. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Li XL; Ménoret S; Le Mauff B; Angin M; Anegon I Transplantation; 2008 Jul; 86(1):10-5. PubMed ID: 18622269 [TBL] [Abstract][Full Text] [Related]
48. Regulatory B cells in autoimmune diseases: how do they work? Lemoine S; Morva A; Youinou P; Jamin C Ann N Y Acad Sci; 2009 Sep; 1173():260-7. PubMed ID: 19758160 [TBL] [Abstract][Full Text] [Related]
50. A novel mammalian display system for the selection of protein-protein interactions by decoy receptor engagement. Ellmark P; Ohlin M; Borrebaeck CA; Furebring C J Mol Recognit; 2004; 17(4):316-22. PubMed ID: 15227638 [TBL] [Abstract][Full Text] [Related]
51. Gene transfer of noncleavable cell surface mutants of human CD154 induces the immune response and diminishes systemic inflammatory reactions. Masuta Y; Kato K; Tomihara K; Nakamura K; Sasaki K; Takahashi S; Hamada H J Immunother; 2007 Oct; 30(7):694-704. PubMed ID: 17893562 [TBL] [Abstract][Full Text] [Related]
52. Prospect of targeting the CD40 pathway for cancer therapy. Vonderheide RH Clin Cancer Res; 2007 Feb; 13(4):1083-8. PubMed ID: 17317815 [TBL] [Abstract][Full Text] [Related]
53. Identification and characterization of functional CD154 (CD40 ligand) in the Pekin duck. Fischer KP; Gares SL; Wang D; Lorne Tyrrell D; Gutfreund KS Dev Comp Immunol; 2007; 31(1):61-71. PubMed ID: 16837046 [TBL] [Abstract][Full Text] [Related]